Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,660 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P, Lonial S; KEYNOTE-183 Investigators. Mateos MV, et al. Among authors: iida s. Lancet Haematol. 2019 Sep;6(9):e459-e469. doi: 10.1016/S2352-3026(19)30110-3. Epub 2019 Jul 18. Lancet Haematol. 2019. PMID: 31327687 Clinical Trial.
Melphalan-prednisolone and vincristine-doxorubicin-dexamethasone chemotherapy followed by prednisolone/interferon maintenance therapy for multiple myeloma: Japan Clinical Oncology Group Study, JCOG0112.
Chou T, Tobinai K, Uike N, Asakawa T, Saito I, Fukuda H, Mizoroki F, Ando K, Iida S, Ueda R, Tsukasaki K, Hotta T; Lymphoma Study Group (LSG) of Japan Clinical Oncology Group (JCOG), Japan. Chou T, et al. Among authors: iida s. Jpn J Clin Oncol. 2011 Apr;41(4):586-9. doi: 10.1093/jjco/hyq245. Epub 2011 Jan 19. Jpn J Clin Oncol. 2011. PMID: 21247967 Clinical Trial.
Lipopolysaccharide-Induced CXCL10 mRNA Level and Six Stimulant-mRNA Combinations in Whole Blood: Novel Biomarkers for Bortezomib Responses Obtained from a Prospective Multicenter Trial for Patients with Multiple Myeloma.
Watanabe T, Mitsuhashi M, Sagawa M, Ri M, Suzuki K, Abe M, Ohmachi K, Nakagawa Y, Nakamura S, Chosa M, Iida S, Kizaki M. Watanabe T, et al. Among authors: iida s. PLoS One. 2015 Jun 26;10(6):e0128662. doi: 10.1371/journal.pone.0128662. eCollection 2015. PLoS One. 2015. PMID: 26115406 Free PMC article.
Phase I study of once weekly treatment with bortezomib in combination with lenalidomide and dexamethasone for relapsed or refractory multiple myeloma.
Totani H, Ri M, Kato C, Nakashima T, Suzuki N, Hagiwara S, Kanamori T, Murakami S, Masuda A, Kinoshita S, Yoshida T, Narita T, Ito A, Kusumoto S, Ishida T, Komatsu H, Iida S. Totani H, et al. Among authors: iida s. Int J Hematol. 2016 Mar;103(3):316-21. doi: 10.1007/s12185-015-1925-7. Epub 2015 Dec 29. Int J Hematol. 2016. PMID: 26715148 Clinical Trial.
A phase 1/2 study of carfilzomib in Japanese patients with relapsed and/or refractory multiple myeloma.
Watanabe T, Tobinai K, Matsumoto M, Suzuki K, Sunami K, Ishida T, Ando K, Chou T, Ozaki S, Taniwaki M, Uike N, Shibayama H, Hatake K, Izutsu K, Ishikawa T, Shumiya Y, Kashihara T, Iida S. Watanabe T, et al. Among authors: iida s. Br J Haematol. 2016 Mar;172(5):745-56. doi: 10.1111/bjh.13900. Epub 2016 Jan 5. Br J Haematol. 2016. PMID: 26732066 Free PMC article. Clinical Trial.
1,660 results